seed
Stage
1
Investors
About
Probmet Therapeutics is a university spin-out based in Copenhagen developing peptide-based targeted therapies for breast cancer brain metastases by targeting the receptor ADAM22; their lead peptide was developed in silico, crosses the blood–brain barrier, and has shown efficacy in human and animal models.
Explore Probmet Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.